ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: Female

Specimen Collected: 12-Sep-23 13:28

OPRM1, 1 Variant | **Received: 12-Sep-23 13:30** **Report/Verified: 14-Sep-23 12:51**

Procedure	Result	Units	Reference Interval
OPRM1,Specimen	Whole Blood		
OPRM1 Genotype,Interpretation	AA		
OPRM1 Phenotype,Interpretation	See Note		
OPRM1,Interpretation	See Note [f1] [i1]		
EER Opioid Receptor,mu OPRM1	See Note [f2]		

Result Footnote

f1: OPRM1, Interpretation

Indication for testing: predict opioid sensitivity.

Interpretation: Two copies of the OPRM1 A allele (rs1799971) were detected in this sample. Increased sensitivity to opioid receptor agonists and decreased sensitivity to opioid receptor antagonists are predicted. This patient may require lower or less frequent doses of opioid receptor agonists (e.g., morphine) to achieve adequate pain control. He/she may also be less likely to respond to opioid antagonists (e.g., naltrexone) in the treatment of alcohol and/or opioid dependency. This association of OPRM1 and drug sensitivity is not definitive and may be different for individual opioids.

Recommendation: Annotations for clinical application of this OPRM1 allele are available through the Pharmacogenomics Knowledge Base at: https://www.pharmgkb.org/gene/PA31945

This result has been reviewed and approved by [redacted]

f2: EER Opioid Receptor, mu OPRM1
Authorized individuals can access the ARUP Enhanced Report using the following link:

[redacted]

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Test Information

i1: OPRM1, Interpretation

BACKGROUND INFORMATION: Opioid Receptor, Mu OPRM1, 1 Variant

CHARACTERISTICS: The mu opioid receptor is involved in mediating the clinical response to opioids (agonists and antagonists). OPRM1 c.118A>G has been associated with lower sensitivity to opioid receptor agonists prescribed for pain control (e.g., morphine) and higher sensitivity to opioid receptor antagonists used in the treatment of alcohol and drug dependency (e.g., naltrexone). Risk of side effects to opioids is also associated with this genetic variant.
INHERITANCE: Autosomal codominant.
CAUSE: SNP rs1799971; OPRM1 c.118A>G (p.Asn40Asp), also known as G allele, alters response to opioids.
CLINICAL SENSITIVITY: Drug dependent.
METHODOLOGY: Polymerase Chain Reaction (PCR) and Fluorescence Monitoring
ANALYTICAL SENSITIVITY and SPECIFICITY: Greater than 99 percent.
LIMITATIONS: Only the targeted OPRM1 mutation, c.118A>G, will be detected. Diagnostic errors can occur due to rare sequence variations. Risk of therapeutic failure or adverse reactions with opioids may be affected by genetic and nongenetic factors that are not detected by this test. This result does not replace the need for therapeutic or clinical monitoring.

Please note the information contained in this report does not contain medication recommendations and should not be interpreted as recommending any specific medications. Any dosage adjustments or other changes to medications should be evaluated in consultation with a medical provider.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.